News
Company News: Curetis to Publish its 2017 Annual Results on April 30, 2018
– Company to host earnings conference call and webcast
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it will publish its full-year 2017 financial results on April 30, 2018. In addition, the Company will host a public earnings conference call and webcast on April 30, 2018, at 03:00 pm CET / 09:00am EDT to present the financial results of 2017, highlight the most important events and provide an outlook for 2018.
Company News: Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018
— UTI panel covers 103 diagnostic targets
— 443-patient multi-center study demonstrates overall weighted average sensitivity of 95.6% at an overall weighted average specificity of 99.3%
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced the successful completion of clinical performance evaluation and CE-IVD marking of its novel Unyvero Application Cartridge, UTI, for the diagnosis of severe urinary tract infections. Unyvero UTI will be launched during the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Madrid, Spain, from April 21 to 24, 2018.
Company News: Prof. Ugur Sahin receives prestigious European Research Council (ERC) Advanced Grant for personalized cancer vaccines
Prof. Ugur Sahin, Managing Director Research and Science at TRON (Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz gGmbH), has been awarded one of the prestigious ERC Advanced Grants 2017 for his project ‘SUMMIT – Stepping Up mRNA Mutanome Immunotherapy’, totaling 2.5 Million Euros over 5 years. The SUMMIT project will be conducted by Prof. Sahin and his team at TRON, an internationally leading research institute in the development of personalized therapy concepts and biomarkers in the field of oncology.
Company News: Curetis: Novel Products and Study Data to be Presented at ECCMID 2018
— Introduction of Unyvero UTI Application Cartridge
— Update on A30 RQ Analyzer to be provided
— MGI/Curetis NGS Solution for Molecular Microbiology to be featured
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company and its subsidiary Ares Genetics GmbH will present novel products, data, and services during this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain, from April 21 – 24, 2018. Curetis and Ares Genetics can be found at booth #79, hall 10, during the conference.